Differential subcellular expression of protein kinase C betaII in breast cancer: Correlation with breast cancer subtypes

Breast Cancer Research and Treatment

Volumn 124, Issue 2, 2010, Pages 327-335

  Gökmen Polar, Yesim ^a   Mehta, Rutika ^a   Tuzmen, Sukru ^b   Mousses, Spyro ^b   Thorat, Mangesh A ^a   Sanders, Kerry L ^a   Turbin, Dmitry ^c   Leung, Samuel ^c   Huntsman, David G ^c   Sledge Jr , George W ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2; Protein kinase C betaII; Subcellular localization; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C BETA; PROTEIN KINASE C BETAII; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATIN-5; KERATIN-6; KI-67 ANTIGEN; PROGNOSIS; PROTEIN KINASE C; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RNA, MESSENGER; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649331684     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0733-2     Document Type: Article

References (52)

1. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lonning AL Borresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
2. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey T Thorsen H Quist JC Matese PO Brown D Botstein PE Lonning AL Borresen-Dale 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. K Podar MS Raab D Chauhan KC Anderson 2007 The therapeutic role of targeting protein kinase c in solid and hematologic malignancies Expert Opin Investig Drugs 16 1693 1707 1:CAS:528:DC%2BD2sXhtFekt7jE 10.1517/13543784.16.10. 1693 17922632 (Pubitemid 350030716)
4. AP Fields NR Murray 2008 Protein kinase c isozymes as therapeutic targets for treatment of human cancers Adv Enzyme Regul 48 166 178 1:CAS:528: DC%2BD1MXhsFGmtbrP 10.1016/j.advenzreg.2007.11.014 18167314
5. CA O'Brian 1989 Elevated protein kinase c expression in human breast tumor biopsies relative to normal breast tissue Cancer Res 49 3215 3217 2720675
6. PC Gordge MJ Hulme RA Clegg WR Miller 1996 Elevation of protein kinase a and protein kinase c activities in malignant as compared with normal human breast tissue Eur J Cancer 32A 2120 2126 1:CAS:528:DyaK2sXpt1Wmsw%3D%3D 10.1016/S0959-8049(96)00255-9 9014755 (Pubitemid 26419463)
7. C Borner R Wyss R Regazzi U Eppenberger D Fabbro 1987 Immunological quantitation of phospholipid/ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors Int J Cancer 40 344 348 1:CAS:528:DyaL2sXmtlCjtrY%3D 10.1002/ijc.2910400310 3623717 (Pubitemid 17156129)
8. SA Lee JW Karaszkiewicz WB Anderson 1992 Elevated level of nuclear protein kinase c in multidrug-resistant mcf-7 human breast carcinoma cells Cancer Res 52 3750 3759 1:CAS:528:DyaK38Xks1amsL4%3D 1617646
9. DA Tonetti M Morrow N Kidwai A Gupta S Badve 2003 Elevated protein kinase c alpha expression may be predictive of tamoxifen treatment failure Br J Cancer 88 1400 1402 1:CAS:528:DC%2BD3sXktFOnsrw%3D 10.1038/sj.bjc.6600923 12778068 (Pubitemid 36606422)
10. JW Assender JM Gee I Lewis IO Ellis JF Robertson RI Nicholson 2007 Protein kinase c isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer J Clin Pathol 60 1216 1221 1:CAS:528:DC%2BD2sXhsVelu7fI 10.1136/jcp.2006.041616 17965220 (Pubitemid 350084541)
11. C Kerfoot W Huang SA Rotenberg 2004 Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase c alpha J Histochem Cytochem 52 419 422 1:CAS:528:DC%2BD2cXhslOgur4%3D 14966210
12. E McKiernan K O'Brien N Grebenchtchikov A Geurts-Moespot AM Sieuwerts JW Martens V Magdolen D Evoy E McDermott J Crown FC Sweep MJ Duffy 2008 Protein kinase cdelta expression in breast cancer as measured by real-time pcr, western blotting and elisa Br J Cancer 99 1644 1650 1:CAS:528:DC%2BD1cXhtlGrurzJ 10.1038/sj.bjc.6604728 19002183
13. Q Pan LW Bao CG Kleer MS Sabel KA Griffith TN Teknos SD Merajver 2005 Protein kinase c epsilon is a predictive biomarker of aggressive breast cancer and a validated target for rna interference anticancer therapy Cancer Res 65 8366 8371 1:CAS:528:DC%2BD2MXhtVShsbnK 10.1158/0008-5472.CAN-05-0553 16166314 (Pubitemid 41330602)
14. S Ali S Al-Sukhun BF El-Rayes FH Sarkar LK Heilbrun PA Philip 2009 Protein kinases c isozymes are differentially expressed in human breast carcinomas Life Sci 84 766 771 1:CAS:528:DC%2BD1MXls1Khtbo%3D 10.1016/j.lfs.2009.03.007 19324060
15. DK Ways CA Kukoly J de Vente JL Hooker WO Bryant KJ Posekany DJ Fletcher PP Cook PJ Parker 1995 Mcf-7 breast cancer cells transfected with protein kinase c-alpha exhibit altered expression of other protein kinase c isoforms and display a more aggressive neoplastic phenotype J Clin Invest 95 1906 1915 1:CAS:528:DyaK2MXkslykurs%3D 10.1172/JCI117872 7706498
16. M Morse-Gaudio JM Connolly DP Rose 1998 Protein kinase c and its isoforms in human breast cancer cells: Relationship to the invasive phenotype Int J Oncol 12 1349 1354 1:CAS:528:DyaK1cXjs1KqtL0%3D 9592198
17. A Manni E Buckwalter R Etindi S Kunselman A Rossini D Mauger D Dabbs L Demers 1996 Induction of a less aggressive breast cancer phenotype by protein kinase c-alpha and -beta overexpression Cell Growth Differ 7 1187 1198 1:CAS:528:DyaK28Xlslahs7w%3D 8877100
18. H Li IB Weinstein 2006 Protein kinase c beta enhances growth and expression of cyclin d1 in human breast cancer cells Cancer Res 66 11399 11408 1:CAS:528:DC%2BD28Xht1KnsL3P 10.1158/0008-5472.CAN-06-2386 17145886 (Pubitemid 46009971)
19. H Yoshiji S Kuriyama DK Ways J Yoshii Y Miyamoto M Kawata Y Ikenaka H Tsujinoue T Nakatani M Shibuya H Fukui 1999 Protein kinase c lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis Cancer Res 59 4413 4418 1:CAS:528: DyaK1MXlvVSmsb4%3D 10485491
20. P Xia LP Aiello H Ishii ZY Jiang DJ Park GS Robinson H Takagi WP Newsome MR Jirousek GL King 1996 Characterization of vascular endothelial growth factor's effect on the activation of protein kinase c, its isoforms, and endothelial cell growth J Clin Invest 98 2018 2026 1:CAS:528:DyaK28XmvVequr8%3D 10.1172/JCI119006 8903320
21. BP Schneider GW Sledge Jr 2007 Drug insight: Vegf as a therapeutic target for breast cancer Nat Clin Pract Oncol 4 181 189 1:CAS:528:DC%2BD2sXjvV2rurc%3D 10.1038/ncponc0740 17327858 (Pubitemid 46358855)
22. SW McLeskey CA Tobias PR Vezza AC Filie FG Kern J Hanfelt 1998 Tumor growth of fgf or vegf transfected mcf-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor Am J Pathol 153 1993 2006 1:CAS:528:DyaK1cXotV2rs7s%3D 9846989
23. MA Troester KA Hoadley T Sorlie BS Herbert AL Borresen-Dale PE Lonning JW Shay WK Kaufmann CM Perou 2004 Cell-type-specific responses to chemotherapeutics in breast cancer Cancer Res 64 4218 4226 1:CAS:528: DC%2BD2cXkvFWlsLo%3D 10.1158/0008-5472.CAN-04-0107 15205334 (Pubitemid 38802426)
24. MD Pegram RS Finn K Arzoo M Beryt RJ Pietras DJ Slamon 1997 The effect of her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 537 547 1:CAS:528:DyaK2sXls1OltLc%3D 10.1038/sj.onc.1201222 9247307
25. S Tuzmen J Kiefer S Mousses 2007 Validation of short interfering rna knockdowns by quantitative real-time pcr Methods Mol Biol 353 177 203 17332642
26. KJ Livak TD Schmittgen 2001 Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method Methods 25 402 408 1:CAS:528:DC%2BD38XhtFelt7s%3D 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
27. BW Sutherland J Kucab J Wu C Lee MC Cheang E Yorida D Turbin S Dedhar C Nelson M Pollak H Leighton Grimes K Miller S Badve D Huntsman C Blake-Gilks M Chen CJ Pallen SE Dunn 2005 Akt phosphorylates the y-box binding protein 1 at ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells Oncogene 24 4281 4292 1:CAS:528: DC%2BD2MXltFKjtr0%3D 10.1038/sj.onc.1208590 15806160 (Pubitemid 40961781)
28. MA Thorat D Turbin A Morimiya S Leung Q Zhang MH Jeng DG Huntsman H Nakshatri S Badve 2008 Amplified in breast cancer 1 expression in breast cancer Histopathology 53 634 641 1:STN:280:DC%2BD1M%2FktlehsQ%3D%3D 10.1111/j.1365-2559.2008.03155.x 19102007 (Pubitemid 352768711)
29. S Badve D Turbin MA Thorat A Morimiya TO Nielsen CM Perou S Dunn DG Huntsman H Nakshatri 2007 Foxa1 expression in breast cancer - correlation with luminal subtype a and survival Clin Cancer Res 13 4415 4421 1:CAS:528: DC%2BD2sXotlGqt78%3D 10.1158/1078-0432.CCR-07-0122 17671124 (Pubitemid 47219708)
30. NA Makretsov DG Huntsman TO Nielsen E Yorida M Peacock MC Cheang SE Dunn M Hayes M van de Rijn C Bajdik CB Gilks 2004 Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma Clin Cancer Res 10 6143 6151 1:CAS:528: DC%2BD2cXnvVOjs70%3D 10.1158/1078-0432.CCR-04-0429 15448001 (Pubitemid 39287520)
31. Ragaz J, Miller K, Badve S, Dayachko Y, Dunn S, Nielsen T, Brodie A, Huntsman D, Bajdik C, Sledge GW (2004) Adverse association of expressed vascular endothelial growth factor and long-term outcome of stage i-iii breast cancer, with coexpression data of vegf, her-2, cox-2, upa, and er. Results from the british columbia tissue microarray project. Proc ASCO 23
32. RL Camp M Dolled-Filhart DL Rimm 2004 X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 7252 7259 1:CAS:528:DC%2BD2cXpsVKltbc%3D 10.1158/1078-0432.CCR-04-0713 15534099 (Pubitemid 39487712)
33. RM Neve K Chin J Fridlyand J Yeh FL Baehner T Fevr L Clark N Bayani JP Coppe F Tong T Speed PT Spellman S DeVries A Lapuk NJ Wang WL Kuo JL Stilwell D Pinkel DG Albertson FM Waldman F McCormick RB Dickson MD Johnson M Lippman S Ethier A Gazdar JW Gray 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 515 527 1:CAS:528:DC%2BD28XhtlCnsrbE 10.1016/j.ccr.2006.10.008 17157791 (Pubitemid 44854747)
34. D Chelouche-Lev CP Miller C Tellez M Ruiz M Bar-Eli JE Price 2004 Different signalling pathways regulate vegf and il-8 expression in breast cancer: implications for therapy Eur J Cancer 40 2509 2518 1:CAS:528: DC%2BD2cXptFKrs7Y%3D 10.1016/j.ejca.2004.05.024 15519527 (Pubitemid 39424968)
35. GN Naumov E Bender D Zurakowski SY Kang D Sampson E Flynn RS Watnick O Straume LA Akslen J Folkman N Almog 2006 A model of human tumor dormancy: An angiogenic switch from the nonangiogenic phenotype J Natl Cancer Inst 98 316 325 10.1093/jnci/djj068 16507828 (Pubitemid 43338211)
36. AC Newton 2001 Protein kinase c: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions Chem Rev 101 2353 2364 1:CAS:528:DC%2BD3MXkslCju7g%3D 10.1021/cr0002801 11749377 (Pubitemid 35373023)
37. JS Parker M Mullins MC Cheang S Leung D Voduc T Vickery S Davies C Fauron X He Z Hu JF Quackenbush IJ Stijleman J Palazzo JS Marron AB Nobel E Mardis TO Nielsen MJ Ellis CM Perou PS Bernard 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160 1167 10.1200/JCO.2008.18.1370 19204204
38. Y Ono U Kikkawa K Ogita T Fujii T Kurokawa Y Asaoka K Sekiguchi K Ase K Igarashi Y Nishizuka 1987 Expression and properties of two types of protein kinase c: alternative splicing from a single gene Science 236 1116 1120 1:CAS:528:DyaL2sXktlCht7Y%3D 10.1126/science.3576226 3576226
39. CE Chalfant H Mischak JE Watson BC Winkler J Goodnight RV Farese DR Cooper 1995 Regulation of alternative splicing of protein kinase c beta by insulin J Biol Chem 270 13326 13332 1:CAS:528:DyaK2MXmtV2iu7c%3D 10.1074/jbc.270.22.13326 7768933
40. AM Martelli N Sang P Borgatti S Capitani LM Neri 1999 Multiple biological responses activated by nuclear protein kinase c J Cell Biochem 74 499 521 1:CAS:528:DyaK1MXltFeqtL8%3D 10.1002/(SICI)1097-4644(19990915)74:4<499::AID- JCB1>3.0.CO;2-X 10440921 (Pubitemid 29372491)
41. AM Martelli C Evangelisti M Nyakern FA Manzoli 2006 Nuclear protein kinase c Biochim Biophys Acta 1761 542 551 1:CAS:528:DC%2BD28Xmt1yksrg%3D 16574477
42. M Fridberg A Servin L Anagnostaki J Linderoth M Berglund O Soderberg G Enblad A Rosen T Mustelin M Jerkeman JL Persson AG Wingren 2007 Protein expression and cellular localization in two prognostic subgroups of diffuse large b-cell lymphoma: higher expression of zap70 and pkc-beta ii in the non-germinal center group and poor survival in patients deficient in nuclear pten Leuk Lymphoma 48 2221 2232 1:CAS:528:DC%2BD2sXht1Krt7bN 10.1080/10428190701636443 17926183 (Pubitemid 350091065)
43. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
44. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2008) The prognostic significance of ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116:53-68
45. GE Konecny YG Meng M Untch HJ Wang I Bauerfeind M Epstein P Stieber JM Vernes J Gutierrez K Hong M Beryt H Hepp DJ Slamon MD Pegram 2004 Association between her-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 1706 1716 1:CAS:528:DC%2BD2cXhvFCltrs%3D 10.1158/1078-0432.CCR-0951-3 15014023 (Pubitemid 38435562)
46. I Zachary 2003 Vegf signalling: integration and multi-tasking in endothelial cell biology Biochem Soc Trans 31 1171 1177 1:CAS:528: DC%2BD3sXps12jsrw%3D 10.1042/BST0311171 14641020
47. YJ Suh S Chada T McKenzie Y Liu SG Swisher A Lucci KK Hunt 2005 Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells Surgery 138 422 430 10.1016/j.surg.2005.06.032 16213894 (Pubitemid 41415568)
48. A Ristimaki A Sivula J Lundin M Lundin T Salminen C Haglund H Joensuu J Isola 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res 62 632 635 1:CAS:528:DC%2BD38Xht1KrtLg%3D 11830510
49. JR Graff AM McNulty KR Hanna BW Konicek RL Lynch SN Bailey C Banks A Capen R Goode JE Lewis L Sams KL Huss RM Campbell PW Iversen BL Neubauer TJ Brown L Musib S Geeganage D Thornton 2005 The protein kinase cbeta-selective inhibitor, enzastaurin (ly317615.Hcl), suppresses signaling through the akt pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462 7469 1:CAS:528:DC%2BD2MXns1Wqsrc%3D 10.1158/0008-5472.CAN-05-0071 16103100 (Pubitemid 41161281)
50. Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD (2009) A phase ii study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs 27:565-570
51. AP Fields SR Calcagno M Krishna S Rak M Leitges NR Murray 2009 Protein kinase cbeta is an effective target for chemoprevention of colon cancer Cancer Res 69 1643 1650 1:CAS:528:DC%2BD1MXhslyntr4%3D 10.1158/0008-5472.CAN-08-3187 19221092
52. MJ Robertson BS Kahl JM Vose S de Vos M Laughlin PJ Flynn K Rowland JC Cruz SL Goldberg L Musib C Darstein N Enas JL Kutok JC Aster D Neuberg KJ Savage A LaCasce D Thornton CA Slapak MA Shipp 2007 Phase ii study of enzastaurin, a protein kinase c beta inhibitor, in patients with relapsed or refractory diffuse large b-cell lymphoma J Clin Oncol 25 1741 1746 1:CAS:528:DC%2BD2sXlvFyktbg%3D 10.1200/JCO.2006.09.3146 17389337 (Pubitemid 46797955)